DK2542079T3 - Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat - Google Patents

Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat

Info

Publication number: DK2542079T3
Authority: DK; Denmark
Prior art keywords: laquinimod; methotrexate; treatment; combination; rheumatoid arthritis
Prior art date: 2010-03-03

Application number

DK11751300.2T

Other languages

English (en)

Inventor

Eran Blaugrund

Nora Tarcic

Joel Kaye

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-03-03

Filing date

2011-03-02

Publication date

2014-08-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44531858&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2542079(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-03-02 Application filed by Teva Pharma filed Critical Teva Pharma

2014-08-25 Application granted granted Critical

2014-08-25 Publication of DK2542079T3 publication Critical patent/DK2542079T3/da

Links

FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title 1
GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 title 1
229960004577 laquinimod Drugs 0.000 title 1
229960000485 methotrexate Drugs 0.000 title 1
206010039073 rheumatoid arthritis Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK11751300.2T 2010-03-03 2011-03-02 Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat DK2542079T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33937510P	2010-03-03	2010-03-03
PCT/US2011/026885 WO2011109531A1 (en)	2010-03-03	2011-03-02	Treatment of rheumatoid arthritis with a combination of laquinimod and methotrexate

Publications (1)

Publication Number	Publication Date
DK2542079T3 true DK2542079T3 (da)	2014-08-25

Family

ID=44531858

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK11751300.2T DK2542079T3 (da)	2010-03-03	2011-03-02	Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat

Country Status (21)

Country	Link
US (1)	US8501766B2 (da)
EP (1)	EP2542079B1 (da)
JP (1)	JP5819328B2 (da)
KR (1)	KR20130014523A (da)
CN (2)	CN105796556A (da)
AU (1)	AU2011223697B2 (da)
BR (1)	BR112012022187A2 (da)
CA (1)	CA2791709A1 (da)
CL (1)	CL2012002424A1 (da)
CO (1)	CO6630085A2 (da)
DK (1)	DK2542079T3 (da)
EA (1)	EA201290860A1 (da)
ES (1)	ES2476368T3 (da)
MX (1)	MX2012010066A (da)
NZ (1)	NZ602478A (da)
PE (1)	PE20130690A1 (da)
PT (1)	PT2542079E (da)
SG (1)	SG183513A1 (da)
SI (1)	SI2542079T1 (da)
WO (1)	WO2011109531A1 (da)
ZA (1)	ZA201207128B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2523762T3 (es) *	2005-10-19	2014-12-01	Teva Pharmaceutical Industries Ltd	Cristales de laquinimod sódico, y procedimientos para su fabricación
RS52169B (en)	2006-06-12	2012-08-31	Teva Pharmaceutical Industries Limited	STABLE LAKVINIMOD PREPARATIONS
PL2682120T3 (pl)	2007-12-20	2017-02-28	Teva Pharmaceutical Industries, Ltd.	Stabilne preparaty lakwinimodu
ES2633658T3 (es) *	2008-09-03	2017-09-22	Teva Pharmaceutical Industries Ltd.	Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
NZ597378A (en) *	2009-06-19	2014-08-29	Teva Pharma	Treatment of multiple sclerosis with laquinimod
DK2458992T3 (da) *	2009-07-30	2016-02-08	Teva Pharma	Behandling af crohn's sygdom med laquinimod
SI2467372T1 (sl)	2009-08-10	2016-09-30	Teva Pharmaceutical Industries Ltd.	Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
PE20130613A1 (es) *	2010-03-03	2013-06-23	Teva Pharma	Tratamiento de lupus nefritis usando laquinimod
AU2011274496B2 (en)	2010-07-09	2016-03-10	Teva Pharmaceutical Industries Ltd.	Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
JP2014530821A (ja)	2011-10-12	2014-11-20	テバファーマシューティカルインダストリーズリミティド	ラキニモドおよびフィンゴリモドを組み合わせた多発性硬化症の治療
EA201491460A1 (ru)	2012-02-03	2015-01-30	Тева Фармасьютикал Индастриз Лтд.	ПРИМЕНЕНИЕ ЛАХИНИМОДА В ЛЕЧЕНИИ ПАЦИЕНТОВ С БОЛЕЗНЬЮ КРОНА, У КОТОРЫХ НЕ ЭФФЕКТИВНА ТЕРАПИЯ ПЕРВОЙ ЛИНИИ АНТИ-TNFα
JP6215238B2 (ja)	2012-02-16	2017-10-18	テバファーマシューティカルインダストリーズリミティド	Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用
TW201350467A (zh)	2012-05-08	2013-12-16	Teva Pharma	Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh)	2012-06-05	2014-01-01	Teva Pharma	使用拉喹莫德治療眼發炎疾病
TW201410244A (zh)	2012-08-13	2014-03-16	Teva Pharma	用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
CA2890194A1 (en)	2012-11-07	2014-05-15	Teva Pharmaceutical Industries Ltd.	Amine salts of laquinimod
JP2016513665A (ja)	2013-03-14	2016-05-16	テバファーマシューティカルインダストリーズリミティド	ラキニモドの経皮製剤
TW201519892A (zh)	2013-03-14	2015-06-01	Teva Pharma	拉喹莫德鈉之結晶及其製造之改良方法
CN106573014A (zh)	2014-04-29	2017-04-19	梯瓦制药工业有限公司	用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德
CN115281149A (zh) *	2021-05-12	2022-11-04	四川大学华西医院	一种临床前类风湿关节炎(Pre-RA)小鼠模型

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2340735A1 (fr)	1976-02-11	1977-09-09	Roussel Uclaf	Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
IE52670B1 (en)	1981-03-03	1988-01-20	Leo Ab	Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
US5540934A (en)	1994-06-22	1996-07-30	Touitou; Elka	Compositions for applying active substances to or through the skin
US5912349A (en)	1997-01-31	1999-06-15	Pharmacia & Upjohn Company	Process for the preparation of roquinimex
US6696407B1 (en)	1997-03-21	2004-02-24	The Regents Of The University Of California	Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US6077851A (en) *	1998-04-27	2000-06-20	Active Biotech Ab	Quinoline derivatives
SE9801474D0 (sv)	1998-04-27	1998-04-27	Active Biotech Ab	Quinoline Derivatives
SE9802550D0 (sv)	1998-07-15	1998-07-15	Active Biotech Ab	Quinoline derivatives
SE9802549D0 (sv)	1998-07-15	1998-07-15	Active Biotech Ab	Quinoline derivatives
US6133285A (en)	1998-07-15	2000-10-17	Active Biotech Ab	Quinoline derivatives
US6121287A (en)	1998-07-15	2000-09-19	Active Biotech Ab	Quinoline derivatives
CN100390148C (zh)	1999-10-25	2008-05-28	活跃生物技术有限公司	用于治疗恶性肿瘤的药物
WO2002007757A2 (en)	2000-07-21	2002-01-31	Lue Tom F	Prevention and treatment of sexual arousal disorders
US6307050B1 (en)	2000-08-29	2001-10-23	R. T. Alamo Venture I Llc	Method of synthesizing flosequinan from 4-fluoroanthranilic acid
US7560557B2 (en)	2002-06-12	2009-07-14	Active Biotech Ag	Process for the manufacture of quinoline derivatives
US6875869B2 (en)	2002-06-12	2005-04-05	Active Biotech Ab	Process for the manufacture of quinoline derivatives
SE0201778D0 (sv)	2002-06-12	2002-06-12	Active Biotech Ab	Process for the manufacture of quinoline derivatives
US20070292461A1 (en)	2003-08-04	2007-12-20	Foamix Ltd.	Oleaginous pharmaceutical and cosmetic foam
JP2007524626A (ja) *	2003-06-25	2007-08-30	エランファーマシューティカルズ，インコーポレイテッド	関節リウマチを治療する方法および組成物
US8795693B2 (en)	2003-08-04	2014-08-05	Foamix Ltd.	Compositions with modulating agents
US8314124B2 (en)	2004-02-06	2012-11-20	Active Biotech Ab	Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv)	2004-02-06	2004-02-06	Active Biotech Ab	New composition containing quinoline compounds
CA2561164A1 (en)	2004-04-01	2005-10-20	Elan Pharmaceuticals, Inc.	Steroid sparing agents and their use
US20090048181A1 (en)	2004-09-02	2009-02-19	Schipper Hyman M	Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
PL1797109T3 (pl)	2004-09-09	2016-11-30		Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
US20060205822A1 (en)	2004-12-22	2006-09-14	Forest Laboratories, Inc.	1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
KR20140077946A (ko)	2005-10-13	2014-06-24	휴먼 게놈 사이언시즈, 인코포레이티드	자가항체 양성 질환 환자의 치료에 유용한 방법 및 조성물
US9168286B2 (en)	2005-10-13	2015-10-27	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive disease
ES2523762T3 (es)	2005-10-19	2014-12-01	Teva Pharmaceutical Industries Ltd	Cristales de laquinimod sódico, y procedimientos para su fabricación
PL1951674T3 (pl) *	2005-10-26	2012-04-30	Merck Serono Sa	Pochodne sulfonamidowe i ich zastosowania do modulowania metaloproteinaz
US20080108641A1 (en)	2006-02-08	2008-05-08	Ajami Alfred M	Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
US8367629B2 (en)	2006-02-14	2013-02-05	Noxxon Pharma Ag	MCP-1 binding nucleic acids and use thereof
PL2676967T3 (pl)	2006-02-28	2019-12-31	Biogen Ma Inc.	Metody leczenia chorób zapalnych i autoimmunologicznych za pomocą natalizumabu
JP2009531304A (ja)	2006-02-28	2009-09-03	エランファーマシューティカルズ，インコーポレイテッド	α−４阻害剤化合物を用いて炎症性疾患および自己免疫疾患を治療する方法
ES2663377T3 (es)	2006-03-03	2018-04-12	Biogen Ma Inc.	Métodos para el tratamiento de enfermedades inflamatorias y autoinmunes con natalizumab
EP2010214A4 (en) *	2006-04-10	2010-06-16	Abbott Biotech Ltd	USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
WO2007139887A2 (en)	2006-05-22	2007-12-06	Cargill, Incorporated	Methods for treating bone or joint inflammation
US20080118553A1 (en)	2006-06-12	2008-05-22	Anton Frenkel	Tannate salt form of polypeptide mixtures, their preparation and use
RS52169B (en)	2006-06-12	2012-08-31	Teva Pharmaceutical Industries Limited	STABLE LAKVINIMOD PREPARATIONS
ATE510538T1 (de)	2006-08-11	2011-06-15	Univ Johns Hopkins	Zusammensetzungen und verfahren für nervenschutz
CN101743018A (zh)	2006-12-19	2010-06-16	梅里麦克药品公司	甲胎蛋白和免疫调谐剂的共同施用以治疗多发性硬化
WO2008085484A2 (en)	2006-12-28	2008-07-17	Jacobus Pharmaceutical Company, Inc.	Treatment of inflammatory bowel disease with enteric coated formulations comprising 5-aminosalicylic acid or 4-aminosalicylic acid
WO2009009529A1 (en)	2007-07-11	2009-01-15	Medicinova, Inc.	Treatment of progressive neurodegenerative disease with ibudilast
PL2682120T3 (pl)	2007-12-20	2017-02-28	Teva Pharmaceutical Industries, Ltd.	Stabilne preparaty lakwinimodu
ES2633658T3 (es)	2008-09-03	2017-09-22	Teva Pharmaceutical Industries Ltd.	Moduladores 2-oxo-1,2-dihidro-quinolina de la función inmunitaria
EP2370436A1 (en)	2008-11-13	2011-10-05	Link Medicine Corporation	Azaquinolinone derivatives and uses thereof
NZ597378A (en)	2009-06-19	2014-08-29	Teva Pharma	Treatment of multiple sclerosis with laquinimod
DK2458992T3 (da)	2009-07-30	2016-02-08	Teva Pharma	Behandling af crohn's sygdom med laquinimod
SI2467372T1 (sl)	2009-08-10	2016-09-30	Teva Pharmaceutical Industries Ltd.	Zdravljenje motenj, povezanih z BDNF, z uporabo lakvinimoda
PE20130613A1 (es)	2010-03-03	2013-06-23	Teva Pharma	Tratamiento de lupus nefritis usando laquinimod
SG10201501539SA (en)	2010-03-03	2015-04-29	Teva Pharma	Treatment of lupus arthritis using laquinimod
AU2011274496B2 (en)	2010-07-09	2016-03-10	Teva Pharmaceutical Industries Ltd.	Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CN102985090B (zh)	2010-07-09	2014-11-26	泰华制药工业有限公司	5-氯-4-羟基-1-甲基-2-氧代-n-苯基-1,2-二氢喹啉-3-甲酰胺、其盐和用途
MX2013006464A (es)	2010-12-07	2013-07-29	Teva Pharma	Uso de laquinimod para reducir la fatiga, mejorada el estado funcional y mejorar la calidad de vida en pacientes con esclerosis multiple.
CN105944081A (zh)	2011-07-28	2016-09-21	泰华制药工业有限公司	用拉喹莫德与醋酸格拉替雷的组合治疗多发性硬化症
SG10201606204TA (en)	2011-07-28	2016-09-29	Teva Pharma	Treatment Of Multiple Sclerosis With Combination Of Laquinimod And Interferon-Beta

2011
- 2011-03-02 EP EP11751300.2A patent/EP2542079B1/en active Active
- 2011-03-02 WO PCT/US2011/026885 patent/WO2011109531A1/en active Application Filing
- 2011-03-02 ES ES11751300.2T patent/ES2476368T3/es active Active
- 2011-03-02 DK DK11751300.2T patent/DK2542079T3/da active
- 2011-03-02 SG SG2012063491A patent/SG183513A1/en unknown
- 2011-03-02 US US13/039,188 patent/US8501766B2/en not_active Expired - Fee Related
- 2011-03-02 KR KR1020127025006A patent/KR20130014523A/ko not_active Application Discontinuation
- 2011-03-02 CA CA2791709A patent/CA2791709A1/en not_active Abandoned
- 2011-03-02 SI SI201130210T patent/SI2542079T1/sl unknown
- 2011-03-02 MX MX2012010066A patent/MX2012010066A/es active IP Right Grant
- 2011-03-02 AU AU2011223697A patent/AU2011223697B2/en not_active Ceased
- 2011-03-02 NZ NZ602478A patent/NZ602478A/en not_active IP Right Cessation
- 2011-03-02 CN CN201610240474.2A patent/CN105796556A/zh active Pending
- 2011-03-02 EA EA201290860A patent/EA201290860A1/ru unknown
- 2011-03-02 PE PE2012001383A patent/PE20130690A1/es not_active Application Discontinuation
- 2011-03-02 PT PT117513002T patent/PT2542079E/pt unknown
- 2011-03-02 BR BR112012022187A patent/BR112012022187A2/pt not_active IP Right Cessation
- 2011-03-02 CN CN2011800121091A patent/CN102781240A/zh active Pending
- 2011-03-02 JP JP2012556213A patent/JP5819328B2/ja not_active Expired - Fee Related
2012
- 2012-08-31 CL CL2012002424A patent/CL2012002424A1/es unknown
- 2012-09-17 CO CO12159942A patent/CO6630085A2/es unknown
- 2012-09-21 ZA ZA2012/07128A patent/ZA201207128B/en unknown

Also Published As

Publication number	Publication date
AU2011223697A1 (en)	2012-10-11
CO6630085A2 (es)	2013-03-01
ES2476368T3 (es)	2014-07-14
EP2542079A1 (en)	2013-01-09
SI2542079T1 (sl)	2014-08-29
JP2013521304A (ja)	2013-06-10
NZ602478A (en)	2014-09-26
CL2012002424A1 (es)	2012-12-21
WO2011109531A1 (en)	2011-09-09
KR20130014523A (ko)	2013-02-07
EA201290860A1 (ru)	2013-04-30
CN102781240A (zh)	2012-11-14
CN105796556A (zh)	2016-07-27
US8501766B2 (en)	2013-08-06
EP2542079A4 (en)	2013-07-24
JP5819328B2 (ja)	2015-11-24
EP2542079B1 (en)	2014-05-21
CA2791709A1 (en)	2011-09-09
PE20130690A1 (es)	2013-07-07
AU2011223697B2 (en)	2016-07-14
PT2542079E (pt)	2014-07-18
BR112012022187A2 (pt)	2015-09-22
ZA201207128B (en)	2014-04-30
SG183513A1 (en)	2012-09-27
MX2012010066A (es)	2012-10-03
US20110218203A1 (en)	2011-09-08

Publication	Publication Date	Title
DK2542079T3 (da)	2014-08-25	Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
DK2483181T3 (da)	2014-08-25	Behandling af reumatoid artritis med en kombination af laquinimod og methotrexat
DK2437783T3 (da)	2014-01-20	Behandling af acinetobacter med alginatoligomerer og antibiotika
DK2691443T3 (da)	2021-05-03	Konjugerede lipomerer og anvendelser af disse
DK2658551T3 (da)	2020-09-21	Behandling af erektil dysfunktion og andre indikationer
CO6950482A2 (es)	2014-05-20	Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización
EP2713727A4 (en)	2014-10-22	COMBINATION OF MEK INHIBITORS AND AURORA A KINASE ALECTIVE INHIBITORS
DK2723347T3 (da)	2019-11-18	Forebyggelse og behandling af inflammationstilstande
DK3494972T3 (da)	2024-01-29	Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
GB201014633D0 (en)	2010-10-13	Rheumatoid arthritis treatment
DK2782570T3 (da)	2019-12-09	Heterocykliske hæmmere af glutaminase
DK2513193T3 (da)	2014-01-27	Forbedrede blends af polyarylenethere og polyarylensulfider
DK2603219T3 (da)	2014-10-13	Kombination af GLYT1-forbindelse med antipsykotika
DK2603226T3 (da)	2021-06-07	Behandling af diabetes med endokrine pankreas-prækursorceller
DK3067578T3 (da)	2020-02-17	Leje med tre og flere rækker af rulleelementer
DK2625174T3 (da)	2015-02-02	Co-krystaller og salte af ccr3-inhibitorer
DK2576810T3 (da)	2017-11-20	Påvisning og tælling af mikroorganismer
DK2531181T3 (da)	2019-07-15	Formuleringer af rasagilin med forlænget afgivelse og anvendelser deraf
DK2596254T3 (da)	2014-08-25	Møtrik og en kombination af en boltedel og en møtrik
DK2646452T3 (da)	2016-06-20	Chlorering af carbohydrater og carbohydratderivater
DK2427417T3 (da)	2014-01-20	Salte af 3-pentylphenyleddikesyre og farmaceutiske anvendelser deraf
DK2668445T3 (da)	2022-01-24	Behandling af affaldsforbrændingsaske
DK2790710T3 (da)	2020-11-30	Amorft calciumcarbonat til behandling af calciummalabsorption og metaboliske knoglelidelser
DK2441419T3 (da)	2020-06-08	Fremgangsmåde til tilvejebringelse af en ble med en tilpasset benåbning
DK2661274T3 (da)	2019-08-26	Sammensætninger og fremgangsmåder med aloepolysaccharider